STAT+: 4 epilepsy-focused biotech companies to watch

More companies than ever before are training their sights on developing treatments for epilepsy, which affects about 3 million adults and half a million children in the U.S.

Though there are a number of anti-seizure drugs on the market, more than 30% of people with the condition have tried at least three different drugs and still experience seizures.

Continue to STAT+ to read the full story…